| 09/22/2026 4:04 PM | Werewolf Therapeutics (1785530) Filer | Form S-4 Registration statement under Securities Act of 1933 | |
| 09/21/2026 10:11 AM | MOLL PETER (1732748) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G | |
| 08/21/2026 8:10 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/21/2026 8:12 AM | Werewolf Therapeutics (1785530) Subject | Form 425 | |
| 08/20/2026 3:06 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/31/2026 6:10 AM | Werewolf Therapeutics (1785530) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/31/2026 6:06 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:34 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:18 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for HOWL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/06/2026 4:19 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:19 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 7:26 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/29/2026 6:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:29 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:30 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:39 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/22/2026 5:59 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 6:02 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/16/2026 5:01 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/15/2026 7:16 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 06/11/2026 7:13 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/10/2026 4:20 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 5:13 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 5:42 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 5:51 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/28/2026 4:02 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:03 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/28/2026 4:04 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/26/2026 5:18 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/20/2026 5:08 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/18/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Elon gets it. Do you? (Ad) Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news.
Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point. Stream the free Ignition Point broadcast for the full biotech breakdown. |
| 05/18/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:02 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/18/2026 4:03 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/14/2026 4:23 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/13/2026 3:06 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 6:56 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/12/2026 6:47 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/12/2026 5:26 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 3:31 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:32 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 3:33 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/07/2026 5:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2026 6:04 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 05/04/2026 5:00 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:52 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:51 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:52 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 6:16 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/29/2026 3:47 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:47 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/29/2026 3:48 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:59 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:00 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 4:01 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 6:07 AM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/27/2026 6:12 AM | Werewolf Therapeutics (1785530) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/24/2026 4:26 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/11/2026 2:46 PM | Longwood Fund III, L.P. (1640546) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13G/A | |
| 02/06/2026 3:41 PM | Werewolf Therapeutics (1785530) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/20/2026 3:07 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/16/2026 4:36 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 01/15/2026 4:22 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 4:09 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 4:12 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/06/2026 3:58 PM | MPM Asset Management Investors BV2014 LLC (1609495) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:59 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Why I went to Mount Rushmore (Ad) A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars.
BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent. Watch the free video and get the stock name now |
| 01/06/2026 3:54 PM | MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:54 PM | MPM BioVentures 2014, L.P. (1609492) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:56 PM | UBS Oncology Impact Fund L.P. (1691428) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/06/2026 3:57 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 4:32 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 5:59 PM | MPM BioVentures 2014, L.P. (1609492) Filed by Werewolf Therapeutics (1785530) Subject | Form SCHEDULE 13D/A | |
| 12/29/2025 4:27 PM | EVNIN LUKE (1134657) Reporting Werewolf Therapeutics (1785530) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:45 PM | MPM ASSET MANAGEMENT LLC (1263048) Reporting Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/29/2025 3:45 PM | MPM BioVentures 2014 (0) B Werewolf Therapeutics (1785530) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |